Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) reported a net loss of $4.97 million for 2024 while the botanical psychedelic drug developer expanded its clinical trial programs and intellectual property portfolio.
The Vancouver-based company announced in its year-end financial results that cash reserves stood at just $391,237 as of Dec….
Please login to read all 412 words.
